Regeneron Pharmaceuticals, Inc. (LON:0R2M)

Market Cap	51.24B
Revenue (ttm)	10.60B
Net Income (ttm)	3.41B
Shares Out	n/a
EPS (ttm)	30.94
PE Ratio	15.04
Forward PE	14.17
Dividend	2.01 (0.31%)
Ex-Dividend Date	Aug 18, 2025

Volume	270
Average Volume	1,033
Open	649.66
Previous Close	652.25
Day's Range	641.66 - 662.74
52-Week Range	477.01 - 834.19
Beta	n/a
RSI	64.95
Earnings Date	Oct 28, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 15,106
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R2M

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD